Lv4
700 积分 2023-02-15 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
3天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
4天前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
4天前
已完结
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
16天前
已完结
Next steps for targeted protein degradation
18天前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
23天前
已关闭
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
23天前
已关闭
The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC
1个月前
已完结
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
1个月前
已完结
RENOIR Trial — RSVpreF Vaccine Efficacy over Two Seasons
1个月前
已完结
Association between expanded criteria for living kidney donors and renal biopsy findings
皖公网安备34019202002308
